← board
ICLR
Bexion Pharmaceuticals, Inc.distress 2/10 · well-funded / low risk$176.09+5%today-13% from 52w high
Oncology 1
Lead: Metastatic Colorectal Carcinoma · est. market ~$12B (approx, global)
Revenue
$2034M
Liquidity
$765M
Runway
—
Shares 1y
0%
Price & events
-5.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.3%
1D
+3.6%
1W
+23.4%
1M
+65.6%
3M
-5.7%
6M
+4.9%
1Y
-47.0%
2Y
-19.2%
5Y
-8.3%
All
Overview
- Market Cap
- $13.48B
- Enterprise Value
- $15.58B
- Volume
- 87.56K
- 52 Week Range
- $80.08 – $203
- Total Shares
- 76.57M
- Float Shares
- 76.27M
- Short %
- 4.38%
- % Held by Insiders
- 0.44%
- % Held by Institutions
- 108.45%
- RVOL
- 0.11x
- Beta
- 1.22
Pipeline stages · 1 programs
BXQ-350
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04 | Phase 1/2 | BXQ-350 | Metastatic Colorectal Carcinoma, Neuropathy | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-07-23Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 76,567,325 · 0 offerings/1y · 0 PIPEs
- 2024-11-12SC 13G/Astrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $182 (+3% upside) · 16 analysts
- 2026-06-30Truist SecuritiesHold → Buy
- 2026-06-26MizuhoOutperform
- 2026-06-25RBC CapitalSector Perform → Outperform
- 2026-06-25BMO CapitalOutperform
- 2026-06-25CitigroupNeutral
- 2026-06-25BarclaysEqual-Weight
Competitors — Metastatic Colorectal Carcinoma
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22ICON Plc (ICLR) is Strengthening After Challenges - Yahoo Finance
- 2026-07-22ICON Schedules Second Quarter 2026 Earnings C - Moomoo
- 2026-07-22ICON plc to announce Q2FY26 results on July 29 - scanx.trade
- 2026-07-22ICON plc (NASDAQ: ICLR) schedules Q2 2026 earnings results call - Stock Titan
- 2026-07-22Press Release: ICON Schedules Second Quarter 2026 Earnings Conference Call - Moomoo
- 2026-07-22ICON Schedules Second Quarter 2026 Earnings Conference Call - Business Wire
- 2026-07-22ICON Schedules Second Quarter 2026 Earnings Conference Call - Business Wire
- 2026-07-21AVTR vs. ICLR: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.